Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5409775 | 1.00 | CYP1A2 (0.50) | CYP1A2HIF1ASLC6A4SLC6A3MEN1 | |
| SCHEMBL5416984 | 0.77 | CYP1A2 (0.43) | CYP1A2HIF1ASLC6A4SLC6A3BRD4 | |
| SCHEMBL5412750 | 0.77 | CYP1A2 (0.43) | CYP1A2HIF1ASLC6A4SLC6A3BRD4 | |
| SCHEMBL5412755 | 0.77 | CYP1A2 (0.43) | CYP1A2HIF1ASLC6A4SLC6A3BRD4 | |
| SCHEMBL5402537 | 0.74 | SLC6A3 (0.50) | CYP1A2HIF1ASLC6A4SLC6A3 | |
| SCHEMBL5398287 | 0.74 | SLC6A3 (0.50) | CYP1A2HIF1ASLC6A4SLC6A3 | |
| SCHEMBL5402528 | 0.74 | SLC6A3 (0.50) | CYP1A2HIF1ASLC6A4SLC6A3 | |
| SCHEMBL18012494 | 0.73 | CYP1A2 (0.59) | CYP1A2HIF1ASLC6A4SLC6A3 | |
| SCHEMBL19807632 | 0.73 | CYP1A2 (0.59) | CYP1A2HIF1ASLC6A4SLC6A3 | |
| SCHEMBL21322442 | 0.73 | CYP1A2 (0.59) | CYP1A2HIF1ASLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070244149-A1 | Tropane analogs and methods for inhibition of monoamine transport | ORGANIX, INC. (US) | 2007-10-18 | — | — | US | disclosed |
| US-7199132-B2 | Tropane analogs and methods for inhibition of monoamine transport | ORGANIX, INC. (US) | 2007-04-03 | — | — | US | disclosed |
| US-20030105125-A1 | Tropane analogs and methods for inhibition of monoamine transport | WILMINGTON TRUST (LONDON) LIMITED, AS SECURITY AGENT (GB) | 2003-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105125-A1 | Tropane analogs and methods for inhibition of monoamine transport | SLC6A2, SLC6A4, SLC6A3 | CYP1A2 235/4885HIF1A 3437/4885SLC6A4 2/4885 |
| US-20070244149-A1 | Tropane analogs and methods for inhibition of monoamine transport | SLC6A2, SLC6A4, SLC6A3 | CYP1A2 235/4885HIF1A 3437/4885SLC6A4 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.